Executive Summary: Solving the Genetic Disease and Rapid Pandemic Response Challenge
RNA therapeutics and vaccines represent a groundbreaking approach to medical interventions that leverage the unique properties of ribonucleic acid. These approaches have gained significant attention, particularly in medicine and biotechnology. RNA therapeutics involve using RNA molecules to treat or prevent diseases by modulating gene expression or protein production. Types: mRNA therapeutics introduce synthetic mRNA into cells to produce specific proteins (genetic disorders, cancers). siRNA therapeutics use short RNA molecules to interfere with specific gene expression, blocking harmful protein production (viral infections, genetic disorders). Antisense oligonucleotide therapeutics utilize short RNA/DNA molecules to bind to target mRNA, modulating translation (neurodegenerative disorders). RNA vaccines use RNA molecules to stimulate immune response against pathogens. Rapid development (e.g., COVID-19 mRNA vaccines in <12 months), high precision targeting, modular adaptability (sequence changes), and personalized medicine potential drive the field. This deep-dive analyzes mRNA vs. siRNA vs. antisense segmentation across hospitals and research institutions.
The global market for RNA therapeutics and vaccines was valued at US28,400millionin2025andisprojectedtoreachUS28,400millionin2025andisprojectedtoreachUS 58,200 million by 2032, growing at a CAGR of 10.8% from 2026 to 2032. Growth driven by COVID-19 mRNA vaccine adoption (Comirnaty, Spikevax, $20B+ annual sales), FDA/EMA approvals for siRNA (Amvuttra, Oxlumo, Leqvio, Givlaari) and antisense (Spinraza, Tegsedi, Waylivra, Qalsody), and expanding pipeline in oncology, cardiovascular, and rare genetic diseases.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5975808/rna-therapeutics-and-vaccines
1. Core Modality Advantages and Clinical Progress
| Modality | Mechanism | Approved Drugs (2026) | Key Advantage | Limitations |
|---|---|---|---|---|
| mRNA | Protein replacement / vaccine antigen | Comirnaty/Pfizer, Spikevax/Moderna (COVID) + pipeline (RSV, flu, CMV, cancer) | Rapid development, scalable manufacturing | Cold chain (-20 to -80°C), inflammatory reactogenicity |
| siRNA (RNAi) | Gene silencing (RISC complex) | Patisiran (Onpattro), inclisiran (Leqvio), vutrisiran (Amvuttra), lumasiran (Oxlumo), givosiran (Givlaari) | Long duration (6-month dosing), durable gene silencing | Liver delivery (GalNAc conjugate required), off-target silencing |
| Antisense Oligonucleotide | Splice modulation / RNase H degradation | Nusinersen (Spinraza), eteplirsen (Exondys 51), golodirsen (Vyondys 53), inotersen (Tegsedi), tofersen (Qalsody) | Well-established chemistry, CNS delivery (Spinraza intrathecal) | Weekly or monthly dosing, injection site reactions |
独家观察 (Exclusive Insight): While mRNA vaccines dominate revenue, the fastest-growing segment since Q4 2025 is extrahepatic delivery for siRNA and antisense (CNS, muscle, lung, kidney). A January 2026 industry report noted 8 siRNA/antisense assets with C16 conjugation (Alnylam’s C16 platform, Arrowhead’s TRiMTM) or peptide targeting (Avidity’s AOC) are in Phase 2/3 for myotonic dystrophy, Huntington’s, ALS, Duchenne, and IgA nephropathy, moving beyond liver. Non-liver targeted RNA therapies command 2-3x higher pricing (500k−1.2M/patient/yearvs.500k−1.2M/patient/yearvs.200-450k for liver targets) but address larger patient populations (10-100x more patients). Alnylam’s C16 preclinical data (2025) shows 10x potency in muscle. Extrahepatic RNA therapeutics market projected 18-20% CAGR 2026-2032, outpacing total RNA market.
2. Segmentation by Modality
| Segment | 2025 Share | Key Approved Drugs | Pipeline Focus | Avg Price (Annual) |
|---|---|---|---|---|
| mRNA (Vaccines + Therapeutics) | 55% | COVID-19 vaccines, RSV (mRESVIA) | CMV, flu, cancer (personalized neoantigen), rare disease protein replacement | 50−150(vaccines),50−150(vaccines),200-500k (therapeutics) |
| siRNA (RNAi) | 25% | Leqvio (PCSK9), Amvuttra (ATTR), Oxlumo (PH1), Givlaari (AHP), Onpattro (ATTR) | Cardiovascular (CKD, hypertension), neurological | 200−450k(raredisease),200−450k(raredisease),2-6k (Leqvio) |
| Antisense Oligonucleotide | 20% | Spinraza (SMA), Exondys 51, Vyondys 53, Tegsedi, Waylivra, Qalsody | Duchenne MD, ALS, Huntington’s, myotonic dystrophy | 300−750k(Spinraza300−750k(Spinraza450k, Tegsedi $450k) |
3. Application Analysis: Hospitals vs. Research Institutions
Hospitals (Academic Medical Centers, Community Oncology) (65% demand): Largest segment (administration of approved RNA drugs). A Q4 2025 hospital pharmacy report noted Spinraza (nusinersen, intrathecal) for SMA administered to 2,500 US patients/year; Leqvio (inclisiran, PCSK9 siRNA) for high cholesterol administered to 45,000 patients (2x/year dosing). Hospital requirement: cold chain (-80°C for mRNA vaccines), intrathecal administration training (Spinraza), patient monitoring for infusion reactions.
Research Institutions (Clinical Trials, Translational Research) (30% demand): A January 2026 clinicaltrials.gov search identified 420 active RNA therapeutic trials (220 mRNA, 120 siRNA, 80 antisense), primarily in academic medical centers. Research requirement: GMP-grade RNA synthesis (lipid nanoparticle encapsulation in-house or outsourced), animal models (transgenic, humanized), in vivo delivery optimization.
Industry Layering Insight: In hospitals (administration), approved RNA drugs (Spinraza, Leqvio, Onpattro, COVID vaccines) increasingly integrated into specialty pharmacy. In research institutions (early discovery), LNP formulation expertise, conjugation chemistry (GalNAc, C16), and animal efficacy models critical.
4. Competitive Landscape and Technical Challenges
Key Suppliers: Moderna (mRNA leader, RSV vaccine mRESVIA, personal cancer vaccine), BioNTech (Pfizer collaborator, COVID Comirnaty, oncology mRNA), Sanofi (acquisition of Translate Bio, mRNA), Novartis (investor, not lead), CureVac (mRNA, COVID), CSL (therapies), Arrowhead Pharmaceuticals (TRiM siRNA platform, ARO-AAT, ARO-ANG3), Alnylam Pharmaceuticals (RNAi pioneer, GalNAc conjugate, C16 extrahepatic platform), GSK (antisense?), Ionis Pharmaceuticals (antisense leader, Spinraza collaborator), Regulus (miRNA, not approved), Roche (partner, not lead), AstraZeneca (partnered with Ionis, eplontersen), Sarepta Therapeutics (DMD antisense), Orna Therapeutics (circular RNA, preclinical).
Technical Challenges: Delivery beyond liver remains greatest hurdle (C16 extrahepatic improvements but still early). Immunogenicity (unmodified RNA triggers TLR3/7/8, cytokine release). Manufacturing scalability (lipid nanoparticle production, mRNA capping efficiency). Long-term off-target effects (siRNA seed region complementarity leads to unintended gene silencing).
Recent Developments (2025–2026): Alnylam reported positive Phase 2 C16-siRNA for myotonic dystrophy (muscle delivery), stock +25% (December 2025). Moderna’s personalized cancer mRNA vaccine (mRNA-4157) + Keytruda extended PFS in melanoma (Phase 2b), Phase 3 initiated (January 2026). Ionis’s tofersen (Qalsody) for SOD1-ALS approved in US (April 2025, accelerated approval based on NfL reduction). Arrowhead’s ARO-AAT for alpha-1 antitrypsin deficiency Phase 3 fully enrolled (January 2026).
5. Forecast and Strategic Recommendations (2026–2032)
| Metric | 2025 Actual | 2032 Projected | CAGR |
|---|---|---|---|
| Global market value | $28,400M | $58,200M | 10.8% |
| Extrahepatic delivery (siRNA/ASO) share | ~5% | ~20% | 18-20% |
| mRNA therapeutics (non-vaccine) share | <1% | ~10% | 30% |
| RNA-based personalized cancer vaccine share | <1% | ~5% | 40% |
- Fastest-growing region: North America (CAGR 11-12%), Europe (CAGR 10-11%), Asia-Pacific (CAGR 12-13%, China mRNA vaccine manufacturing + cancer research).
- Fastest-growing segment: Extrahepatic delivery RNA therapeutics (CAGR 18-20%).
- Price trends: Rare disease RNA drugs increasing (+5-7% annually) due to small patient populations; cardiovascular/metabolic RNA drugs (Leqvio) stable/declining (-2-3% with volume); mRNA vaccines stable for seasonal indications ($50-150/dose).
Conclusion: RNA therapeutics and vaccines have revolutionized genetic medicine, infectious disease prevention, and oncology. Global Info Research recommends investors focus on extrahepatic delivery platforms (Alnylam’s C16, Arrowhead’s TRiMTM, Avidity’s AOC) for large market potential; clinicians familiarize with approved siRNA/antisense drugs (Spinraza, Leqvio, Amvuttra, Qalsody) for rare diseases; researchers invest in LNP formulation and conjugation chemistry expertise. As delivery expands beyond liver, RNA therapies will address increasingly prevalent neurological, muscular, and renal diseases.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
